news
Nanobodies developed to image COVID-19 Spike protein
Researchers in the UK have selected nanobodies that bind with high affinity to the Spike protein on the COVID-19 coronavirus, enabling stabilisation for imaging.
List view / Grid view
Drug targets
news
Severe COVID-19 symptoms may be caused by overactive neutrophils
An international consortium suggest that the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS), could be caused by Neutrophil Extracellular Traps (NETs).
article
The coronavirus as a personalised enemy of mankind
How has evolution led us to the point where humans are an ideal host for SARS-CoV-2, the virus that causes the COVID-19 coronavirus?
article
Gender-specific coronavirus infections in the light of evolution
Dr Kutschera discusses the differences between males and females in relation to infection from the COVID-19 coronavirus.
news
Human lung epithelium model being tested as a platform for COVID-19 research
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
news
Scientists identify fusion peptide as promising COVID-19 drug target
Researchers working on related coronaviruses SARS and MERS have identified the membrane fusion peptide on the Spike protein as a possible drug target for SARS-CoV-2, the virus causing COVID-19.
news
Receptors enabling COVID-19 infection found on cilia progenitor cells, study shows
Sequencing almost 60,000 cells, researchers have found that certain cilia progenitor cells have gene transcripts for ACE2 and co-factor TMPRSS2, enabling COVID-19 infection.
news
Researchers reveal how SARS antibody binds to COVID-19 coronavirus
The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.
news
Celltrion to select lead antibody candidates to fight COVID-19
Following the screening of antibodies, Celltrion will now identify the most potent out of 300 hits that work against the COVID-19 coronavirus best.
news
Decoy ACE2 receptors could be promising COVID-19 infection-preventing drug
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
news
Free access to AI Clinical Research Navigator tool for COVID-19 researchers
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
news
Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
article
Host pathways in coronavirus replication and COVID-19 pre-clinical drug target identification using proteomic and chemoinformatic analysis
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
news
Remdesivir most promising COVID-19 drug, say researchers
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
news
Collaboration initiated to develop COVID-19 immunotherapy
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
